POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine aims to stop Virus-Linked cancers in transplant patients
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tests a vaccine (OSU-2131) designed to help the immune system fight Epstein-Barr virus (EBV), which can cause cancer in people with weakened immune systems, such as organ transplant recipients. The study includes healthy volunteers and patients waiting for …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 17, 2026 03:09 UTC
-
Engineered immune cells take aim at returning blood cancers
Disease control OngoingThis early-stage study tests a personalized cell therapy for adults with certain B-cell blood cancers (like lymphomas and leukemias) that have come back after prior treatment. Doctors take a patient's own white blood cells, modify them in the lab to better recognize and attack ca…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Engineered immune cells target tough lymphoma after transplant
Disease control OngoingThis early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goals are to check safety and find the best …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 05, 2026 12:10 UTC